Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

This study has been completed.
Information provided by (Responsible Party):
Therapeutic Advances in Childhood Leukemia Consortium Identifier:
First received: February 23, 2007
Last updated: June 29, 2012
Last verified: June 2012